Stockscreener 앱 받기
55.95
21.91%
-15.70
전일 마감가:
$71.65
열려 있는:
$71.63
하루 거래량:
4.91M
Relative Volume:
7.79
시가총액:
$2.11B
수익:
-
순이익/손실:
$-91.00M
주가수익비율:
-15.25
EPS:
-3.67
순현금흐름:
$-74.38M
1주 성능:
-29.82%
1개월 성능:
-25.84%
6개월 성능:
-8.43%
1년 성능:
+3.42%
1일 변동 폭
$40.00
$73.97
1주일 범위
$40.00
$79.80
52주 변동 폭
$30.82
$99.50
Disc Medicine Inc Stock (IRON) Company Profile
명칭
Disc Medicine Inc
전화
(617) 674-9274
주소
321 ARSENAL STREET, SUITE 101, WATERTOWN
Compare IRON vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IRON
Disc Medicine Inc
|
55.95 | 2.70B | 0 | -91.00M | -74.38M | -3.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Disc Medicine Inc Stock (IRON) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-03 | 재개 | Stifel | Buy |
| 2025-07-21 | 개시 | Truist | Buy |
| 2025-07-03 | 재개 | Morgan Stanley | Overweight |
| 2025-06-11 | 재개 | Raymond James | Strong Buy |
| 2025-02-27 | 개시 | TD Cowen | Buy |
| 2024-11-05 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-11-04 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-10-23 | 개시 | Jefferies | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-08-22 | 개시 | Wells Fargo | Overweight |
| 2024-04-01 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2023-12-19 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-06-09 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2023-06-07 | 개시 | H.C. Wainwright | Buy |
| 2023-05-17 | 개시 | Raymond James | Outperform |
| 2023-04-28 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-04-21 | 개시 | Stifel | Buy |
| 2023-04-20 | 개시 | Morgan Stanley | Overweight |
| 2023-03-23 | 개시 | BMO Capital Markets | Outperform |
| 2023-02-28 | 개시 | SVB Securities | Outperform |
모두보기
Disc Medicine Inc 주식(IRON)의 최신 뉴스
Disc Medicine stock slumps after FDA declines approval for inherited disorder drug over efficacy concerns - MSN
Disc Medicine (IRON) Drops 22% After FDA Response on Bitopertin - GuruFocus
Drug For Rare Genetic Disorder Goes From FDA Priority to Reject in Four Months - Bloomberg.com
Disc setback deepens questions about FDA’s accelerated approval commitment, value of new vouchers - biocentury.com
Disc Medicine plunges on FDA Complete Response Letter for bitopertin (IRON:NASDAQ) - Seeking Alpha
Disc Medicine Receives FDA Complete Response on Bitopertin - TipRanks
Breaking: US FDA’s Bitopertin CRL Shows CNPV Cannot Overcome Surrogate Endpoint Woes - Citeline News & Insights
FDA Issues Complete Response Letter to Bitopertin For Erythropoietic Protoporphyria - HCPLive
Disc Medicine EPP Treatment Fails to Get FDA Accelerated Approval - marketscreener.com
Disc Medicine (NASDAQ:IRON) Trading Down 40%What's Next? - MarketBeat
Disc Medicine stock plunges after FDA issues Complete Response Letter - Investing.com
FDA issues complete response letter for Disc Medicine’s EPP drug By Investing.com - Investing.com Canada
Disc Medicine Stock Slumps After FDA Declines Approval For Inherited Disorder Drug Over Efficacy Concerns - Stocktwits
Significant Drop for IronNet Stock (IRON) Amid Late-Day Trading - GuruFocus
FDA Responds to Bitopertin Application with Complete Response Letter - Intellectia AI
Disc Medicine Receives Complete Response Letter From FDA For Bitopertin For The Treatment Of EPP - TradingView
Disc Medicine plunges after FDA posts complete response letter for bitopertin - TipRanks
Disc Medicine confirms complete response letter from FDA for bitopertin - TipRanks
Disc Medicine (IRON) Addresses FDA Concerns with Confidence - GuruFocus
Disc Medicine Receives Complete Response Letter from FDA for Bitopertin for the Treatment of EPP - The Manila Times
US FDA declines to approve Disc Medicine's rare disease drug - Reuters
FDA Issues Complete Response Letter for Disc Medicine’s Bitopertin, Awaiting APOLLO Study Results for Potential Approval - Quiver Quantitative
FDA delays decision on rare disease drug, pushing verdict to 2027 - Stock Titan
Breakout Move: Is Disc Medicine Inc stock trending bullishWeekly Investment Recap & Community Driven Trade Alerts - baoquankhu1.vn
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc.- IRON - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Disc Medicine, Inc. (IRON) And Encourages Shareholders to Reach Out - ACCESS Newswire
2026-02-11 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Disc Medicine, Inc. (IRON) And Encourages Shareholders to Reach Out | NDAQ:IRON | Press Release - Stockhouse
Why retail investors favor Disc Medicine Inc. stockJuly 2025 Spike Watch & Safe Capital Preservation Plans - mfd.ru
Disc Medicine, Inc. (IRON) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Disc Medicine, Inc. (NASDAQ:IRON) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
getLinesFromResByArray error: size == 0 - mfd.ru
Bronstein, Gewirtz & Grossman, LLC Is Investigating Disc Medicine, Inc. (IRON) And Encourages Investors to Connect - ACCESS Newswire
Hedge Fund Bets: Whats the beta of Disc Medicine Inc stockJuly 2025 Action & Entry Point Confirmation Alerts - baoquankhu1.vn
What Investors Should Know About a $511K Disc Medicine Insider Sale and a 26% Stock Run - AOL.com
Disc Medicine, Inc. (IRON) Investor Outlook: Unveiling a 51% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, ... - Bluefield Daily Telegraph
Trend Review: Will Disc Medicine Inc outperform during market rallies2025 Technical Overview & Daily Momentum Trading Reports - baoquankhu1.vn
Responsive Playbooks and the IRON Inflection - Stock Traders Daily
2026-02-01 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Disc Medicine, Inc. (IRON) And Encourages Stockholders to Connect | NDAQ:IRON | Press Release - Stockhouse
Atle Fund Management AB Purchases 21,038 Shares of Disc Medicine, Inc. $IRON - MarketBeat
Disc Medicine, Inc. (IRON) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - accessnewswire.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Disc Medicine, Inc. (IRON) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
BMO Capital reaffirms Disc Medicine stock rating amid approval optimism By Investing.com - Investing.com Canada
Bronstein, Gewirtz & Grossman, LLC Encourages Disc Medicine, Inc. (IRON) Investors to Inquire about Securities Investigation - accessnewswire.com
Y Intercept Hong Kong Ltd Purchases 33,905 Shares of Disc Medicine, Inc. $IRON - MarketBeat
Wall Street Analysts Believe Disc Medicine, Inc. (IRON) Could Rally 48.62%: Here's is How to Trade - Yahoo Finance
Disc Medicine, Inc. (IRON) Stock Analysis: Biotech Innovator With A 57% Upside Potential - DirectorsTalk Interviews
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Disc Medicine, Inc. (IRON) And Encourages Investors to Reach Out - ACCESS Newswire
Report of FDA Drug Approval Delay is 'Likely Noise': Analyst - streetwisereports.com
Pomerantz LLP Investigates Securities Fraud Claims Against Disc Medicine - Intellectia AI
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Disc Medicine, Inc. – IRON - Chartmill
Disc Medicine Inc (IRON) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.12%
0.87%
자본화:
|
볼륨(24시간):